Acute kidney injury

There are 894 papers on acute kidney injury in aging research: 40 trials and 449 observational studies in people, 179 in animals, 1 in cells, 185 reviews. The newest story, Nov 17, 2026: “Frailty linked to death in kidney injury survivors off dialysis”.

Disease

894 papers study it173 more mention it468 findings

MeSH

122 new papers in 30 daysSee all 1,067 papers on acute kidney injury

At a glance

Acute kidney injury is linked with higher mortality in hospitalized very old adults, while frailty is associated with higher injury risk across surgical cohorts. Human observational studies also link PhenoAge acceleration and clonal hematopoiesis with higher risk. A nicotinamide mononucleotide trial and a metformin trial reported as a preprint show no clear effect on acute kidney injury.

468 findings in 376 papers from 2015 to 2026, 102 of them since April 2026

“The risk of acute kidney injury was significantly lower among SGLT2i users compared with placebo [risk ratio (RR) 0.73; 95% CI 0.62-0.87].”
Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trialsDiabetes, obesity & metabolism2023doi:10.1111/dom.15193
  • Human trial40
  • Humans449
  • Animals179
  • Cells1
  • In silico5

Interventions

59

SGLT2 inhibitors

no changein humans7downin humans7HR 0.56–0.98

14 studies
  1. SGLT2 inhibitors were not clearly linked with acute kidney injury in humans (aHR 0.74, 95% CI 0.50–1.10).

    “SGLT2i initiation was not associated with increased 90-day AKI risk (aHR, 0.74; 95% CI, 0.50–1.10)”

    HumansType 2 diabetes mellitus and chronic kidney disease; compared with dipeptidyl peptidase-4 inhibitor initiation90 daysn = 43,502

    Diabetes drug class not linked to higher kidney injury risk

    Diabetes research and clinical practice

  2. SGLT2 inhibitors were not clearly linked with acute kidney injury in humans (isolated surgical aortic valve replacement for nonrheumatic aortic stenosis) (6.1% vs 9.6%; HR 0.68, 95% CI 0.44–1.05).

    “acute kidney injury (6.1% vs 9.6%; HR 0.68, 95% CI 0.44-1.05”

    Humansisolated surgical aortic valve replacement for nonrheumatic aortic stenosis30 to 365 days after SAVR

    Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes After Isolated Surgical Aortic Valve Replacement

    AHA Scientific Sessions 2026 abstract

  3. SGLT2 inhibitors were not clearly linked with acute kidney injury in humans.

    “neither SGLT2-i use, GLP-1 RA use, nor dual therapy was associated with differences in the odds of any-stage AKI compared with controls.”

    HumansType 2 diabetes mellitus undergoing elective on-pump cardiac surgery; monotherapy compared with no medications

    Association of GLP-1 Receptor Agonists and SGLT2 Inhibitors with Renal Outcomes After Cardiac Surgery

    AHA Scientific Sessions 2026 abstract

  4. SGLT2 inhibitors were not clearly linked with acute kidney injury in humans (HFrEF and concurrent active malignancy) (HR 0.957; p=0.236).

    “Acute kidney injury rates were similar on time-to-event analysis (hazard ratio 0.957; p=0.236).”

    HumansHFrEF and concurrent active malignancy3 years

    Drugs tied to survival in weak-pumping heart failure and active cancer

    AHA Scientific Sessions 2026 abstract

  5. SGLT2 inhibitors were not clearly linked with acute kidney injury in humans (continuation for 3 months after TAVI versus discontinuation, propensity-matched cohorts) (HR 0.98, 95% CI 0.79–1.20).

    “with no increased risk of acute kidney injury (HR 0.98, 95% CI 0.79–1.20, p=0.82)”

    Humanscontinuation for 3 months after TAVI versus discontinuation, propensity-matched cohorts1 yearn = 1,104

    Continued sodium-glucose cotransporter-2 inhibitors linked to survival

    ESC Congress 2026 abstract

  6. SGLT2 inhibitors were not clearly linked with acute kidney injury in humans (heart failure patients after TAVR, propensity score-matched cohort) (32.6% vs. 27.9%; RR 1.168 (95% CI 0.991-1.378)).

    “AKI (32.6% vs. 27.9%; RR=1.168, 95% CI: 0.991-1.378, p=0.063)”

    Humansheart failure patients after TAVR, propensity score-matched cohortn = 660

    SGLT2 inhibitors improve clinical outcomes in patients with heart failure undergoing transcatheter aortic valve replacement: real world evidence from the trinetx database

    ESC Congress 2026 abstract

  7. SGLT2 inhibitors are linked with lower acute kidney injury in humans (preoperative use within 1 year before index procedure; propensity score-matched cohort) (15.4% vs 17.7%; RR 0.870).

    “Acute kidney injury at 30 days was lower with SGLT2 inhibitors (15.4% vs. 17.7%; RR 0.870, p < 0.001)”

    Humanspreoperative use within 1 year before index procedure; propensity score-matched cohort30 daysn = 7,526

    Preoperative SGLT2 Inhibitor Use and Outcomes After Major Cardiac Procedures: A Propensity Score-Matched Analysis of the TriNetX Network

    Journal of clinical medicine

  8. SGLT2 inhibitors were not clearly linked with acute kidney injury in humans (propensity-score-matched patients with type 2 diabetes undergoing TEER) (31.7% vs 32.9%).

    “There were no significant differences in MACE (52.0 vs. 46.2%, P = 0.136) or AKI (31.7 vs. 32.9%, P = 0.737).”

    Humanspropensity-score-matched patients with type 2 diabetes undergoing TEER1 yearn = 325

    Outcomes of SGLT2 inhibitors after transcatheter mitral valve repair in patients with type 2 diabetes mellitus

    Journal of cardiovascular medicine (Hagerstown, Md.)

  9. SGLT2 inhibitors are linked with lower acute kidney injury in humans (compared with other second-line glucose-lowering drugs; target trial emulation) (average individual treatment effect -0.0039 (95% CI -0.0065 to -0.0014)).

    “SGLT2 inhibitors were associated with a significant reduction in AKI compared with other second-line glucose-lowering drugs, with an average individual treatment effect of -0.0039 (95% CI: -0.0065 to -0.0014).”

    Humanscompared with other second-line glucose-lowering drugs; target trial emulation

    Heterogeneous Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Acute Kidney Injury: A Causal Learning Approach

    medRxiv : the preprint server for health sciencesPreprint

  10. SGLT2 inhibitors are linked with lower acute kidney injury in humans (people with dementia, versus DPP4 inhibitors) (IRD -39.7 per 1000 person-years (95% CI -55.0 to -24.4); NNT 76).

    “For safety outcomes, SGLT2i vs DPP4i initiators with dementia showed less acute kidney injury (IRD -39.7 [-55.0, -24.4]; NNT: 76)”

    Humanspeople with dementia, versus DPP4 inhibitorsn = 2,481

    Cardiovascular effectiveness and safety of SGLT2 inhibitors vs DPP4 inhibitors by dementia status: a cohort study of older adults with diabetes

    Diabetologia

All 14

More on SGLT2 inhibitors

Caloric restriction

downin mice3downin rats3downin humans1downin reviews1+1

9 studies
  1. Caloric restriction decreases acute kidney injury in humans (preoperative formula diet before cardiac surgery) (41.7% in CR group vs 47.5% in control group; reduced by 5.8%).

    “Incidence of acute kidney injury was reduced by 5.8% (41.7% in the CR group compared with 47.5% in the control group).”

    Human trialpreoperative formula diet before cardiac surgeryformula diet60% of the daily energy requirement7 days before surgeryn = 82

    Preoperative Short-Term Calorie Restriction for Prevention of Acute Kidney Injury After Cardiac Surgery: A Randomized, Controlled, Open-Label, Pilot Trial

    Journal of the American Heart Association

  2. Caloric restriction protects against acute kidney injury in murine models of AKI and CKD induced by aristolochic acid or folic acid.

    “Cycles of caloric restriction yielded similar nephroprotection.”

    Animalsin murine models of AKI and CKD induced by aristolochic acid or folic acidkidney

    Caloric restriction protects from acute and chronic kidney injury by inhibiting monocyte recruitment

    iScience

  3. Caloric restriction prevents acute kidney injury in ovary-intact animals with AKI.

    “The present study indicated that CR is more effective than TR in preventing AKI, probably by increasing SIRT1 and decreasing TGF-β1 in ovary-intact animals.”

    Animalsin ovary-intact animals with AKI8 weeksfemales

    Caloric and time restriction diets improve acute kidney injury in experimental menopausal rats: role of silent information regulator 2 homolog 1 and transforming growth factor beta 1

    Molecular biology reports

  4. Caloric restriction decreases acute kidney injury in ovary-intact rats with glycerol-induced AKI.

    “CR improved kidney indicators and caused a reduction in TGF-β1 and an increase in SIRT1 in ovary-intact rats.”

    Animalsin ovary-intact rats with glycerol-induced AKI8 weeksfemales

    Caloric and time restriction diets improve acute kidney injury in experimental menopausal rats: role of silent information regulator 2 homolog 1 and transforming growth factor beta 1

    Molecular biology reports

  5. Caloric restriction prevents acute kidney injury in rodent AKI models.

    “caloric restriction (CR) and transient hypoxia significantly prevent AKI”

    Reviewin rodent AKI models

    Organ Protection by Caloric Restriction Depends on Activation of the De Novo NAD+ Synthesis Pathway

    Journal of the American Society of Nephrology : JASN

  6. Caloric restriction protects against acute kidney injury in rats (ischemic acute kidney injury model).

    “We observed that CR afforded OXYS rats with significant nephroprotection.”

    Animalsischemic acute kidney injury modelkidney

    Calorie Restriction Provides Kidney Ischemic Tolerance in Senescence-Accelerated OXYS Rats

    International journal of molecular sciences

  7. Caloric restriction protects against acute kidney injury in mice (ischemia reperfusion injury).

    “Kidney ischemia reperfusion injury robustly induced acute kidney injury in male mice and this damage could be markedly attenuated by pretreatment with caloric restriction.”

    Animalsischemia reperfusion injurymales

    Caloric restriction reduces the pro-inflammatory eicosanoid 20-hydroxyeicosatetraenoic acid to protect from acute kidney injury

    Kidney international

  8. Caloric restriction protects against acute kidney injury in rats.

    “The results indicated that TR and CR diets had renoprotective effects against AKI by reducing the Bax/Bcl2 ratio and improving apoptosis.”

    Animalsafter glycerol-induced AKI in ovariectomized and sham rats; greater effect than time-restricted feedingkidney8 weeksfemales

    Effects of caloric and time restriction diets on kidney health in rat model of postmenopausal acute kidney injury: An apoptosis and histopathological study

    Iranian journal of basic medical sciences

  9. Caloric restriction protects against acute kidney injury in rodent models of acute kidney injury.

    “Caloric restriction (CR)-mediated organ protection has been shown to be extremely efficient in rodent models of acute kidney injury (AKI).”

    Reviewin rodent models of acute kidney injury

    Mechanisms of Caloric Restriction-Mediated Stress-Resistance in Acute Kidney Injury

    Nephron

  10. Caloric restriction protects against acute kidney injury.

    “DR was shown to ameliorate acute kidney injury (AKI) and chronic kidney disease (CKD).”

    Review

    Dietary Restriction for Kidney Protection: Decline in Nephroprotective Mechanisms During Aging

    Frontiers in physiology

More on Caloric restriction

GLP-1 receptor agonists

downin humans3no changein humans2no changein reviews1OR 0.686–0.76

6 studies
  1. GLP-1 receptor agonists were not clearly linked with acute kidney injury in humans.

    “neither SGLT2-i use, GLP-1 RA use, nor dual therapy was associated with differences in the odds of any-stage AKI compared with controls.”

    HumansType 2 diabetes mellitus undergoing elective on-pump cardiac surgery; monotherapy compared with no medications

    Association of GLP-1 Receptor Agonists and SGLT2 Inhibitors with Renal Outcomes After Cardiac Surgery

    AHA Scientific Sessions 2026 abstract

  2. GLP-1 receptor agonists are linked with lower acute kidney injury in humans after knee extensor mechanism repair (9.71% vs 13.55%; OR 0.686).

    “acute kidney injury (9.71% vs 13.55%; OR = 0.686; P = .0474)”

    Humansafter knee extensor mechanism repair2 years

    Association of GLP-1 Agonists With Postoperative Complications Following Knee Extensor Mechanism Repair:An Analysis of 1,092 Patients

    Orthopedics

  3. GLP-1 receptor agonists were not clearly linked with acute kidney injury in humans (90-day postoperative period).

    “No significant association was observed between GLP-1RAs use and odds of acute kidney injury (P > .05).”

    Humans90-day postoperative period

    GLP-1RAs Use and Postoperative Outcomes in T2DM Patients Undergoing Radical Nephrectomy

    Clinical genitourinary cancer

  4. GLP-1 receptor agonists are linked with lower acute kidney injury in humans (preoperative use before nephrectomy; propensity-matched cohort) (OR 0.76).

    “Those on GLP-1RA therapy had significantly lower odds of 90-day AKI (OR = 0.76; P = .031)”

    Humanspreoperative use before nephrectomy; propensity-matched cohort90 days

    Perioperative and Renal Outcomes After Nephrectomy in Patients Receiving Glucagon-Like Peptide-1 Receptor Agonists: A Pilot Study

    Urology practice

  5. GLP-1 receptor agonists are linked with lower acute kidney injury in humans (patients with T2DM and ESRD compared with matched non-users) (10.45% vs. 14.04%, OR 0.715, CI 0.591-0.865).

    “The rate of AKI was lower in the patients receiving GLP-1 receptor agonists (10.45% vs. 14.04%, OR 0.715, CI 0.591-0.865, p = 0.0005).”

    Humanspatients with T2DM and ESRD compared with matched non-usersat least 6 months of therapyn = 2,009

    MON-521 GLP-1 Receptor Agonists and Risk for Dialysis, Cardiovascular Disease and Mortality in Patients with Type 2 Diabetes Mellitus and End Stage Renal Disease

    ENDO 2025 abstract

  6. GLP-1 receptor agonists showed no clear effect on acute kidney injury.

    “GLP-1RAs do not significantly increase AKI risk and may even confer renal benefits in high-risk populations”

    Review

    Safety and Tolerability of Glucagon-Like Peptide-1 Receptor Agonists: A State-of-the-Art Narrative Review

    Drugs

More on GLP-1 receptor agonists

Nicotinamide mononucleotide

downin mice3no changein humans1

4 studies
  1. Nicotinamide mononucleotide showed no clear effect on acute kidney injury in humans.

    “The changes in serum creatinine levels from baseline over the 14‐day intervention period did not differ significantly between groups.”

    Human trial14 consecutive daysn = 42

    Oral MIB-626 (β Nicotinamide Mononucleotide) Safely Raises Blood Nicotinamide Adenine Dinucleotide Levels in Hospitalized Patients With COVID-19 and Acute Kidney Injury: A Randomized Controlled Trial

    FASEB bioAdvances

  2. Nicotinamide mononucleotide decreases acute kidney injury in mice (acute kidney injury).

    “PEGylation increased the preferential uptake of NMN in mice renal cortex, enhancing its alleviating effect on AKI.”

    Animalsacute kidney injuryPEGylatedkidney

    Modified compound reduced acute kidney injury in mice

    International journal of biological sciences

  3. Nicotinamide mononucleotide protects against acute kidney injury in Kynu-/- mice.

    “Supplementation with nicotinamide mononucleotide, an NAD + precursor, significantly alleviated AKI in Kynu-/- mice.”

    Animalsin Kynu-/- micekidneyfemales

    Sex Dimorphism of NAD +De Novo Biosynthesis Mediates Sex-Biased Susceptibility to Ischemia-Reperfusion-Induced Acute Kidney Injury

    Journal of the American Society of Nephrology : JASN

  4. Nicotinamide mononucleotide protects against acute kidney injury in mice (cisplatin-induced AKI).

    “supplementation with NMN significantly protected mice in both age groups from cisplatin-induced AKI”

    Animalscisplatin-induced AKIkidney

    Nicotinamide Mononucleotide, an NAD⁺ Precursor, Rescues Age-Associated Susceptibility to AKI in a Sirtuin 1-Dependent Manner

    Journal of the American Society of Nephrology : JASN

More on Nicotinamide mononucleotide

Metformin

no changein humans1upin mice1downin mice1downin reviews1

4 studies
  1. Metformin showed no clear effect on acute kidney injury in humans.

    “This indicates that continuing metformin in patients with preserved renal function does not increase the risk of CI-AKI.”

    Human trial72 hoursn = 204

    Is Routine Metformin Discontinuation Necessary Before Elective Coronary Angiography? A Randomized Clinical Trial

    Research SquarePreprint

  2. Metformin increases acute kidney injury in mice (experimentally induced AKI).

    “metformin, even at low doses, exacerbated experimentally-induced acute kidney injury (AKI)”

    Animalsexperimentally induced AKIkidneylow doses

    Metformin potentiates nephrotoxicity by promoting NETosis in response to renal ferroptosis

    Cell discovery

  3. Metformin protects against acute kidney injury in mice.

    “pharmacological stimulation (metformin) protected mice against AKI”

    Animals

    AMPK activation coupling SENP1-Sirt3 axis protects against acute kidney injury

    Molecular therapy : the journal of the American Society of Gene Therapy

  4. Metformin protects against acute kidney injury in acute kidney disease animal models.

    “metformin protects renal tubular cells from inflammation, apoptosis, reactive oxygen stress (ROS), endoplasmic reticulum (ER) stress”

    Reviewin acute kidney disease animal models

    Mechanism and application of metformin in kidney diseases: An update

    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

More on Metformin

Dapagliflozin

no changein humans1downin humans1downin rats1

3 studies
  1. Dapagliflozin decreases acute kidney injury in humans.

    “acute kidney injury was reduced, all regardless of age”

    Human trial

    Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study

    Diabetes care

  2. Dapagliflozin was not clearly linked with acute kidney injury in humans (Acute heart failure; compared with empagliflozin).

    “rates of acute kidney injury were similar between groups.”

    HumansAcute heart failure; compared with empagliflozinIn-hospital

    Early in-hospital initiation of dapagliflozin versus empagliflozin in acute heart failure: impact on in-hospital survival and safety

    ESC Congress 2026 abstract

  3. Dapagliflozin decreases acute kidney injury in rats (diclofenac-induced acute kidney injury; SD rats).

    “While DAPA and MON alone partially mitigated these effects”

    Animalsdiclofenac-induced acute kidney injury; SD ratskidneymales

    Renoprotective effects of dapagliflozin and montelukast for diclofenac induced acute kidney injury through network pharmacology and experimental validation

    Scientific reports

More on Dapagliflozin

Tirzepatide

no changein humans1upin humans1

2 studies
  1. Tirzepatide was not clearly linked with acute kidney injury in humans (FAERS reports, disproportionality analysis).

    “Other GLP-1RAs such as Tirzepatide and Dulaglutide demonstrated no associations with AKI”

    HumansFAERS reports, disproportionality analysis

    MON-527 Association of Acute kidney injury with commonly prescribed glucagon-like peptide 1 receptor Agonists: A Pharmacovigilance Analysis

    ENDO 2025 abstract

  2. Tirzepatide is linked with acute kidney injury in humans (patients with HFrEF receiving GDMT) (2 of 3 patients).

    “Two cases had acute kidney injury owing to tirzepatide's direct vasodilation, natriuresis, reduction in extracellular volume, and weight loss.”

    Humanspatients with HFrEF receiving GDMTn = 2

    Call to action for drug interactions between tirzepatide and heart failure guideline-directed medical therapy

    Journal of the American Pharmacists Association : JAPhA

More on Tirzepatide

Dasatinib + quercetin

downin mice2

2 studies
  1. Dasatinib + quercetin decreases acute kidney injury in mice (kidney IRI model).

    “Oral administration of senolytics also alleviated kidney injury induced by IRI”

    Animalskidney IRI modelkidneymales

    Human umbilical cord mesenchymal stem cells-derived extracellular vesicles ameliorate kidney ischemia-reperfusion injury by suppression of senescent tubular epithelial cells: experimental study

    International journal of surgery (London, England)

  2. Dasatinib + quercetin protects against acute kidney injury in glycerol-induced RM-AKI.

    “which correlated with prolonged nephroprotection in RM-AKI”

    Animalsin glycerol-induced RM-AKIkidney

    Single-cell RNA sequencing identifies senescence as therapeutic target in rhabdomyolysis-induced acute kidney injury

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

More on Dasatinib + quercetin

Dietary restriction

no changein rats1downin rats1

2 studies
  1. Dietary restriction showed no clear effect on acute kidney injury in rats (old rats).

    “in old rats, even 8-week DR was not able to ameliorate AKI”

    Animalsold ratskidney8 weeks

    Resemblance and differences in dietary restriction nephroprotective mechanisms in young and old rats

    Aging

  2. Dietary restriction protects against acute kidney injury in rats (ischemic injury model).

    “DR afforded a significant nephroprotection to ischemic kidneys of young rats.”

    Animalsischemic injury modelkidneyshort-term

    Mechanisms of Age-Dependent Loss of Dietary Restriction Protective Effects in Acute Kidney Injury

    Cells

More on Dietary restriction

Avasopasem manganese

downin humans1downin mice1

1 study
  1. Avasopasem manganese decreases acute kidney injury in cisplatin-treated patients.

    “AVA reduced age-associated therapy-induced adverse events (AE), including hypomagnesemia, increased creatinine, and AKI.”

    Human trialin cisplatin-treated patients

    The antioxidant and anti-inflammatory activities of avasopasem manganese in age-associated, cisplatin-induced renal injury

    Redox biology

  2. Avasopasem manganese decreases acute kidney injury in cisplatin-treated mice.

    “AVA reduced cisplatin-induced mortality, AKI, and CKD, in older animals.”

    Animalsin cisplatin-treated mice

    The antioxidant and anti-inflammatory activities of avasopasem manganese in age-associated, cisplatin-induced renal injury

    Redox biology

More on Avasopasem manganese

Empagliflozin

no changein humans1

1 study
  1. Empagliflozin showed no clear effect on acute kidney injury in humans.

    “There were no statistically significant differences between groups in genitourinary tract infections, life-threatening infections, in-hospital mortality, length of hospitalization, or acute kidney injury.”

    Human trialPatients undergoing elective isolated coronary artery bypass grafting; compared with placebo10 mg once dailyn = 467

    Empagliflozin reduced abnormal heart rhythms after bypass surgery

    ESC Congress 2026 abstract

More on Empagliflozin

Physiology-guided complete revascularization

no changein humans1HR 1.11

1 study
  1. Physiology-guided complete revascularization showed no clear effect on acute kidney injury in humans (older MI patients with multivessel disease) (HR: 1.11; 95% CI: 0.87-1.43).

    “Contrast-associated acute kidney injury occurred in 245 patients (17%), increased progressively across Kidney Disease: Improving Global Outcomes (KDIGO) stages (P < 0.001), and was similar between treatment arms (HR: 1.11; 95% CI: 0.87-1.43).”

    Human trialolder MI patients with multivessel disease

    Renal Function-Stratified Comparison of Complete vs Culprit-Only Revascularization in Older Patients With Myocardial Infarction and Multivessel Disease

    JACC. Cardiovascular interventions

More on Physiology-guided complete revascularization

Anti-obesity medications

no changein humans1RR 0.98

1 study
  1. Anti-obesity medications showed no clear effect on acute kidney injury in humans (weight reduction mediated by AOMs vs placebo) (RR 0.98 (95% CI 0.78 to 1.21)).

    “or acute kidney injury (RR = 0.98, 95%CI, 0.78 to 1.21)”

    Human trialweight reduction mediated by AOMs vs placebo

    The Antiobesity Medications and Renal Outcomes, One Answer But with Multiple Implications—A Meta-analysis of Randomized Controlled Trials

    ADA Scientific Sessions 2025 abstract

More on Anti-obesity medications

All 59

Effects

11

Mortality

mediatesin humans2upin humans1OR 1.43

3 studies
  1. Acute kidney injury mediates mortality in people with diabetes (OR = 1.43, Sobel test p = 0.048).

    “mortality was significantly higher (OR = 1.43, Sobel test p = 0.048) in people with diabetes and ADRs causing AKI.”

    Human trialin people with diabetes

    Diabetes mellitus increases risk of adverse drug reactions and death in hospitalised older people: the SENATOR trial

    European geriatric medicine

  2. Acute kidney injury is linked with mortality in humans (post-hip fracture surgery in frail patients).

    “The effect of these markers on mortality was significantly mediated by their effect on postoperative AKI.”

    Humanspost-hip fracture surgery in frail patients

    Preoperative inflammatory biomarkers reveal renal involvement in postsurgical mortality in hip fracture patients: an exploratory study

    Frontiers in immunology

  3. Acute kidney injury is linked with higher mortality in humans (post-AKI survivors who recovered renal function) (HR = 3.375; 95% CI 2.241-5.083; P < 0.001).

    “mortality at 12 month was higher in the patient with recurrent AKI as compared with those with a single episode (HR = 3.375; 95% CI 2.241-5.083; P < 0.001).”

    Humanspost-AKI survivors who recovered renal function12 months

    Recurrent acute kidney injury in elderly patients is common and associated with 1-year mortality

    International urology and nephrology

NAD+

downin animals1downin reviews1

2 studies
  1. Acute kidney injury decreases NAD+.

    “NAD+ was notably decreased and negatively correlated with kidney dysfunction in AKI”

    Animalskidney

    NAD⁺ ameliorates endotoxin-induced acute kidney injury in a sirtuin1-dependent manner via GSK-3β/Nrf2 signalling pathway

    Journal of cellular and molecular medicine

  2. Acute kidney injury decreases NAD+.

    “In acute kidney injury (AKI), substantial decreases in the levels of NAD+ impair energy generation”

    Reviewrenal tubule

    NAD⁺ homeostasis in renal health and disease

    Nature reviews. Nephrology

More on NAD+

Length of stay

upin humans1

1 study
  1. Acute kidney injury is linked with higher length of stay in humans (critically ill) (+2.8 days, 2.3-3.3).

    “length of ICU (+2.8 days, 2.3-3.3) and hospital stay (+2.3 days, 0.9-3.7)”

    Humanscritically illn = 1,054

    Acute kidney injury predicts mortality in very elderly critically-ill patients

    European journal of internal medicine

PLSCR3PROTEINEXPRESSION

upin humans1

1 study
  1. Acute kidney injury is linked with higher PLSCR3PROTEINEXPRESSION in kidneys of patients with AKI.

    “PLSCR3 protein expression was found to be increased in the kidneys of patients with AKI.”

    Humansin kidneys of patients with AKIkidney

    Genome-Wide CRISPR Screen Identifies Phospholipid Scramblase 3 as the Biological Target of Mitoprotective Drug SS-31

    Journal of the American Society of Nephrology : JASN

More on PLSCR3PROTEINEXPRESSION

Functional Independence Measure

downin humans1

1 study
  1. Acute kidney injury is linked with lower Functional Independence Measure in humans (chronic kidney disease).

    “were also discharged with lower functional independence measure scores”

    Humanschronic kidney diseasen = 183

    Acute Kidney Injury and Rehabilitation Outcomes among Elderly Patients with Chronic Kidney Disease

    Kidney & blood pressure research

More on Functional Independence Measure

PARD3

upin humans1

1 study
  1. Acute kidney injury is linked with higher PARD3 in humans (early acute kidney injury).

    “genes related to epithelial polarity (e.g., PARD3) that were increased in early AKI and decreased in T cell-mediated rejection (TCMR)”

    Humansearly acute kidney injurykidney

    Discovering novel injury features in kidney transplant biopsies associated with TCMR and donor aging

    American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons

More on PARD3

Whole-blood NAD+

downin humans1

1 study
  1. Acute kidney injury decreases whole-blood NAD+ in patients receiving placebo (-50% at 48 h vs 0 h).

    “AKI resulted in a 50% reduction in whole blood NAD+ levels at 48 h compared to 0 h in patients receiving placebo (p = 0.05).”

    Human trialin patients receiving placebowhole blood48 hn = 4

    Nicotinamide riboside with pterostilbene (NRPT) increases NAD⁺ in patients with acute kidney injury (AKI): a randomized, double-blind, placebo-controlled, stepwise safety study of escalating doses of NRPT in patients with AKI

    BMC nephrology

More on Whole-blood NAD+

ICU length of stay

upin humans1

1 study
  1. Acute kidney injury is linked with higher ICU length of stay in humans (abdominal surgery) (3 vs 0 days).

    “AKI patients had significantly longer ICU stay (3 vs 0 days; p<0.001) and higher in-hospital mortality (23.08% vs 2.31%; p<0.001)”

    Humansabdominal surgery

    Incidence, risk factors and outcomes of postoperative acute kidney injury in elderly patients undergoing abdominal surgery

    Preprint

Renal cortical P21 expression

upin mice1

1 study
  1. Acute kidney injury increases renal cortical P21 expression in mice (ischemia-reperfusion or maleate-induced AKI) (marked, progressive).

    “AKI induced marked, progressive, increases in renal cortical p21 mRNA and protein levels.”

    Animalsischemia-reperfusion or maleate-induced AKIrenal cortex2-18 h

    Plasma and urinary p21: potential biomarkers of AKI and renal aging

    American journal of physiology. Renal physiology

More on Renal cortical P21 expression

Plasma P21 concentration

upin mice1

1 study
  1. Acute kidney injury increases plasma P21 concentration in mice (ischemia-reperfusion or maleate-induced AKI) (up to 200-fold).

    “These changes were marked by acute (within 2-4 h) and profound increases (up to 200×) in both plasma and urine p21 concentrations.”

    Animalsischemia-reperfusion or maleate-induced AKI2-4 h

    Plasma and urinary p21: potential biomarkers of AKI and renal aging

    American journal of physiology. Renal physiology

More on Plasma P21 concentration

All 11

Upstream

27

Anemia

mediatesin humans1no changein humans1

2 studies
  1. Anemia was not clearly linked with acute kidney injury in humans (undergoing colorectal cancer surgery).

    “Anemia severity was not significantly associated with ICU or hospital LOS, ARF, or early invasive ventilation.”

    Humansundergoing colorectal cancer surgery

    Associations of early postoperative anemia with mortality and ICU outcomes in nonagenarians and centenarians undergoing colorectal cancer surgery: a binational multicenter propensity matching study

    World journal of surgical oncology

  2. Anemia is linked with acute kidney injury in humans (indirect effect of SGLT2 inhibitors in mediation analysis) (small indirect effect).

    “anemia and heart failure contributed small but statistically significant indirect effects”

    Humansindirect effect of SGLT2 inhibitors in mediation analysis

    Heterogeneous Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Acute Kidney Injury: A Causal Learning Approach

    medRxiv : the preprint server for health sciencesPreprint

More on Anemia

NFE2L2

downin mice1is required forin mice1

2 studies
  1. NFE2L2 protects against acute kidney injury in cisplatin-induced acute kidney injury.

    “Nrf2 deficiency aggravated cisplatin-induced acute kidney injury by exacerbating NOX4-Nrf2 redox imbalance and defective mitophagy”

    Animalsin cisplatin-induced acute kidney injury

    Aging-related NOX4-Nrf2 redox imbalance increases susceptibility to cisplatin-induced acute kidney injury by regulating mitophagy

    Life sciences

  2. NFE2L2 is required for acute kidney injury in mice (OIP-mediated protection, shown by Nrf2 knockout mice).

    “Nrf2-/- mice also did not develop significant OIP-mediated protection against ischemic ARF.”

    AnimalsOIP-mediated protection, shown by Nrf2 knockout micekidney

    Mechanisms and consequences of oxidant-induced renal preconditioning: an Nrf2-dependent, P21-independent, anti-senescence pathway

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

More on NFE2L2

SIRT1

is required forin mice1downin reviews1

2 studies
  1. SIRT1 is required for acute kidney injury in mice.

    “SIRT1 deficiency blunted the protective effect of NMN”

    Animalsprotective effect of NMN against cisplatin-induced AKI, shown by SIRT1 heterozygous deficiencykidney

    Nicotinamide Mononucleotide, an NAD⁺ Precursor, Rescues Age-Associated Susceptibility to AKI in a Sirtuin 1-Dependent Manner

    Journal of the American Society of Nephrology : JASN

  2. SIRT1 protects against acute kidney injury.

    “resists acute kidney injury, delays kidney fibrogenesis”

    Reviewkidney

    SIRT1 and Kidney Function

    Kidney diseases (Basel, Switzerland)

More on SIRT1

Absolute and relative intraoperative hypotension thresholds

no changein humans1

1 study
  1. Absolute and relative intraoperative hypotension thresholds were not clearly linked with acute kidney injury in humans (Patients undergoing hip fracture surgery).

    “Absolute and relative IOH thresholds were not significantly associated with outcomes.”

    HumansPatients undergoing hip fracture surgery69.8% femalesn = 473

    Intraoperative hypotension in older adults with hip fracture: a comparative analysis of different definitions

    European geriatric medicine

More on Absolute and relative intraoperative hypotension thresholds

ERBB2IP

downin mice1

1 study
  1. ERBB2IP protects against acute kidney injury in mice (tubule-specific deletion).

    “Tubule-specific deletion of Erbin rendered mice highly susceptible to acute kidney injury, and exacerbated renal fibrosis.”

    Animalstubule-specific deletionkidney

    Loss of Erbin in tubular epithelial cells sensitizes mice to acute kidney injury and aggravates renal fibrosis

    The EMBO journal

More on ERBB2IP

POM121

downin mice1

1 study
  1. POM121 protects against acute kidney injury in mice (ischemia-reperfusion injury).

    “POM121 haploinsufficiency significantly aggravated renal dysfunction and tubular injury after IRI”

    Animalsischemia-reperfusion injury

    Genetic haploinsufficiency of POM121 exacerbates ischemia reperfusion injury induced acute kidney injury by promoting p53/p21-mediated cellular senescence

    Tissue & cell

More on POM121

MYD88

upin mice1

1 study
  1. MYD88 increases acute kidney injury in SA-AKI (CLP model), shown by tubular epithelial cell-specific deletion.

    “tubular epithelial cell-specific deletion of Myd88 significantly reduced cellular senescence, inflammatory infiltration, and renal injury following SA-AKI.”

    Animalsin SA-AKI (CLP model), shown by tubular epithelial cell-specific deletionkidney

    Inhibition of MyD88 in Tubular Epithelial Cells Alleviates the Cellular Senescence in Sepsis-Associated Acute Kidney Injury

    Inflammation

More on MYD88

IER3

upin mice1

1 study
  1. IER3 increases acute kidney injury in mice after SAKI.

    “knockout of IER3 reduced mortality rates, alleviated renal injury, mitigated renal maladaptive fibrotic repair, and concurrently inhibited RTEC stress-induced senescence after SAKI”

    Animalsafter SAKI

    IER3 drives the transition from sepsis-associated AKI to CKD by suppressing the mitochondrial translocation of PRDX5

    Cellular and molecular life sciences : CMLS

More on IER3

Heart failure

mediatesin humans1

1 study
  1. Heart failure is linked with acute kidney injury in humans (indirect effect of SGLT2 inhibitors in mediation analysis) (small indirect effect).

    “anemia and heart failure contributed small but statistically significant indirect effects”

    Humansindirect effect of SGLT2 inhibitors in mediation analysis

    Heterogeneous Effects of Sodium-Glucose Cotransporter-2 Inhibitors on Acute Kidney Injury: A Causal Learning Approach

    medRxiv : the preprint server for health sciencesPreprint

More on Heart failure

Functional status

no changein humans1OR 1.05

1 study
  1. Functional status was not clearly linked with acute kidney injury in patients undergoing cardiac surgery (OR 1.05, 95% CI 0.85-1.30, p = 0.660).

    “Although no significant association was detected between BI and AKI in the multivariable logistic regression model”

    Humansin patients undergoing cardiac surgeryn = 2,226

    The Impact of Functional Status Assessed by the Barthel Index on Postoperative Outcomes in Patients Undergoing Cardiac Surgery: A Retrospective Cohort Study

    Journal of cardiothoracic and vascular anesthesia

More on Functional status

All 27

Associations

166

SGLT2 inhibitors

downin humans32upin humans5mixedin humans1downin reviews1+6.2% patientsRR 0.52–1.483

39 studies
  1. SGLT2 inhibitors lower the risk of acute kidney injury in humans (versus placebo) (RR 0.73; 95% CI 0.62-0.87).

    “The risk of acute kidney injury was significantly lower among SGLT2i users compared with placebo [risk ratio (RR) 0.73; 95% CI 0.62-0.87].”

    Human trialversus placebo

    Safety of sodium-glucose cotransporter 2 inhibitors in elderly patients with type 2 diabetes: A meta-analysis of randomized controlled trials

    Diabetes, obesity & metabolism

  2. SGLT2 inhibitors are associated with acute kidney injury in humans (Type 2 diabetes; compared with DPP-4 inhibitors after propensity score matching) (8.4% vs 9.9%; risk ratio 0.853, 95% CI 0.839–0.868).

    “Renal outcomes showed lower acute kidney injury (AKI) with SGLT2i (8.4% vs 9.9%; risk ratio 0.853, 95% CI 0.839-0.868; HR 0.768)”

    HumansType 2 diabetes; compared with DPP-4 inhibitors after propensity score matching5 years

    Comparative Cardiovascular Outcomes of SGLT2 Inhibitors versus DPP-4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matched Real-World Analysis

    AHA Scientific Sessions 2026 abstract

  3. SGLT2 inhibitors are linked with a lower risk of acute kidney injury in humans (Type 2 diabetes; compared with DPP-4 inhibitor initiation) (HR 0.76, 95% CI 0.60-0.95).

    “SGLT2i initiation was associated with lower risks of acute kidney injury (HR 0.76, 95% CI 0.60-0.95)”

    HumansType 2 diabetes; compared with DPP-4 inhibitor initiation

    Diabetes drug class not clearly linked to added harm in adults 75-plus

    Diabetes care

  4. SGLT2 inhibitors are associated with acute kidney injury in humans (LVAD recipients without diabetes receiving contemporary GDMT) (HR 0.47–0.51).

    “adjunctive SGLT2 inhibitor therapy was associated with significantly lower mortality, acute kidney injury, and sepsis across short- and intermediate-term follow-up”

    HumansLVAD recipients without diabetes receiving contemporary GDMT2 years

    Sodium–glucose cotransporter-2 inhibitors as adjunctive therapy in left ventricular assist device recipients without diabetes: a real-world cohort study

    ESC Congress 2026 abstract

  5. SGLT2 inhibitors are associated with acute kidney injury in humans (Type 2 diabetes mellitus; compared with DPP-4 inhibitors) (HR 0.55, 95% CI 0.51–0.59).

    “acute kidney injury (AKI) (1.06‰ vs. 1.91‰; HR, 0.55; 95% CI, 0.51-0.59)”

    HumansType 2 diabetes mellitus; compared with DPP-4 inhibitors

    Diabetes drugs linked to fewer harms but more genital infections

    Diabetic medicine : a journal of the British Diabetic Association

  6. SGLT2 inhibitors are associated with acute kidney injury in humans (12.1%).

    “AKI was the most frequent adverse event (12.1%)”

    Humans

    Safety & efficacy of sodium glucose co-transport 2 (SGLT2) inhibitors in elderly patients with heart failure

    Frontiers in cardiovascular medicine

  7. SGLT2 inhibitors are linked with a higher risk of acute kidney injury in humans (propensity-matched adults aged 80 years or older with chronic kidney disease).

    “Risk of acute kidney injury was higher in the SGLT2i group”

    Humanspropensity-matched adults aged 80 years or older with chronic kidney diseasetwo yearsn = 10,076

    Efficacy and Safety of Sodium-Glucose Cotransporter 2 Inhibitors in the Very Elderly with Chronic Kidney Disease: a Retrospective Cohort Study Using Real-World Data

    medRxivPreprint

  8. SGLT2 inhibitors are associated with acute kidney injury in humans (59 (31.1%) within 1-30 days).

    “A substantial proportion of AKI-related hospitalizations occurred within 30 days after SGLT2i initiation.”

    Humansemergency hospitalization within 1-30 days of initiation compared with 31-90 and 91-180 daysn = 190

    Temporal distribution of acute kidney injury-related hospitalizations after initiation of sodium-glucose cotransporter 2 inhibitors: A nationwide claims database analysis in older adults with an independent complementary single-center eGFR analysis

    Journal of diabetes investigation

  9. SGLT2 inhibitors are associated with acute kidney injury in humans (all AKI events occurred in the heart failure subgroup) (6.2% of patients).

    “AEs included AKI (6.2%), urinary tract infection (5.1%), symptomatic hypoglycemia (1.7%), fracture (1.7%), and mycotic infection (0.6%).”

    Humansall AKI events occurred in the heart failure subgroup

    Real-World Safety and Clinical Outcomes of SGLT2 Inhibitors in 195 Pediatric Patients

    ADA Scientific Sessions 2026 abstract

  10. SGLT2 inhibitors are associated with acute kidney injury in humans (type 2 diabetes mellitus following hospitalization for pneumonia) (RR 0.89, 95% CI 0.84–0.94).

    “AKI (RR: 0.89, 95% CI: 0.84-0.94, p < 0.0001)”

    Humanstype 2 diabetes mellitus following hospitalization for pneumonian = 6,505

    A diabetes drug class linked to fewer deaths after pneumonia

    Sage open chronic disease

All 39

More on SGLT2 inhibitors

Mortality

upin humans24HR 1.41–6.73

24 studies
  1. Acute kidney injury is associated with mortality in humans (Intensive care patients).

    “Patients with AKI presented increased mortality rates and an increased need for mechanical ventilation and vasopressors.”

    HumansIntensive care patientsn = 120

    Impact of frailty on acute kidney injury in patients followed-up in the intensive care unit

    Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES

  2. Acute kidney injury is associated with mortality in humans (Both ICD-coded and undiagnosed acute kidney injury).

    “Both AKI groups were strongly associated with coronary heart disease, heart failure, stroke, and mortality.”

    HumansBoth ICD-coded and undiagnosed acute kidney injuryn = 5,692

    Undiagnosed kidney injury linked to heart disease and death

    Kidney medicine

  3. Acute kidney injury predicts mortality in myxofibrosarcoma patients undergoing surgical resection (HR 6.73, p = 0.0005).

    “AKI occurred in 38.8% of patients and independently predicted decreased overall survival (HR 6.73; p = 0.0005).”

    Humansin myxofibrosarcoma patients undergoing surgical resectionn = 49

    Acute kidney injury predicts mortality, sarcopenia and postoperative morbidity in myxofibrosarcoma patients undergoing surgical resection

    World journal of surgical oncology

  4. Acute kidney injury is associated with mortality in patients with hip fractures (p = 0.001).

    “AKI development was also significantly associated with increased mortality (p = 0.001).”

    Humansin patients with hip fracturesn = 190

    Prevalence and risk factors of acute kidney injury in patients with hip fractures

    Journal of perioperative practice

  5. Acute kidney injury is linked with a higher risk of mortality in humans.

    “Acute renal failure and invasive ventilation had a significantly increased hazard of death in the intensive care unit and hospital admission.”

    Humansn = 89

    Characteristics and outcomes of nonagenarians admitted to the intensive care unit: A single-centre observational study

    Anaesthesia and intensive care

  6. Acute kidney injury predicts mortality in humans (critically ill geriatric patients in the ICU) (adjusted HR=2.36, 95% CI: 1.16, 3.68).

    “Acute kidney injury (adjusted HR=2.36, 95% CI: 1.16, 3.68)”

    Humanscritically ill geriatric patients in the ICUn = 296

    Pattern of disease and predictors of mortality among critically ill geriatric patients admitted to intensive care unit at a teaching hospital in Ethiopia: a retrospective cohort study

    BMJ open

  7. Acute kidney injury predicts mortality in humans (postoperative hip fracture surgery) (OR 3.92, 95 % CI 1.97-7.82).

    “AKI (OR 3.92, 95 % CI 1.97-7.82, P < 0.000)”

    Humanspostoperative hip fracture surgery

    Trends and mortality in hip fracture surgery among octogenarians, nonagenarians, and centenarians: high postoperative mortality in centenarians despite few comorbidities

    Injury

  8. Acute kidney injury is associated with mortality in humans (post-hip fracture surgery in frail patients) (OR 10.57, 95% CI 2.76-40.51).

    “The incidence of postoperative AKI (25.4%) was strongly associated with 6-month mortality, odds ratio = 10.57; 95% CI [2.76-40.51]”

    Humanspost-hip fracture surgery in frail patients6-month

    Preoperative inflammatory biomarkers reveal renal involvement in postsurgical mortality in hip fracture patients: an exploratory study

    Frontiers in immunology

  9. Acute kidney injury is linked with a higher risk of mortality in humans (postoperative) (OR 4.58, 95% CI [4.09, 5.13]).

    “acute renal failure (OR: 4.58 95% CI [4.09, 5.13], P < 0.001), pneumonia (95% CI [2.72, 3.83], P < 0.001), and myocardial infarctions (OR: 2.65, 95% CI [1.80, 3.92], P < 0.001) increased likelihood of death after undergoing HHA.”

    Humanspostoperative

    Factors that influence the mortality of patients following hip hemiarthroplasty

    Arthroplasty (London, England)

  10. Acute kidney injury is linked with a higher risk of mortality in humans (elderly patients admitted with hip fractures).

    “severe AKI (stages 2 and 3) was independently associated with increased one-year mortality.”

    Humanselderly patients admitted with hip fracturesone yearn = 1,955

    Comorbidities, acute kidney injury and long-term mortality in elderly patients hospitalized because of hip fracture: a moderation analysis

    Aging clinical and experimental research

All 25

Frailty

upin humans18OR 1.95–15.91

18 studies
  1. Frailty is associated with acute kidney injury in humans.

    “The incidence of AKI was significantly higher among patients classified as frail according to the CFS (p=0.002).”

    HumansUnadjusted analysis; frailty assessed by the Clinical Frailty Scale in intensive care patientsn = 120

    Impact of frailty on acute kidney injury in patients followed-up in the intensive care unit

    Ulusal travma ve acil cerrahi dergisi = Turkish journal of trauma & emergency surgery : TJTES

  2. Frailty is associated with acute kidney injury in humans (Patients undergoing transcatheter aortic valve implantation; adjusted analysis) (OR 3.48, 95% CI 1.26–14.4).

    “Frailty was independently associated with increased in-hospital mortality and postprocedural AKI”

    HumansPatients undergoing transcatheter aortic valve implantation; adjusted analysispostproceduraln = 1,260

    Prognostic value of the modified frailty index-5 for early and long-term outcomes in patients undergoing transcatheter aortic valve implantation

    BMC geriatrics

  3. Frailty is associated with acute kidney injury in humans after T-TEER.

    “frailty was associated with higher rates of MAE (29.8% vs 16.9%; odds ratio 2.09, 95% CI 1.03–4.26; P = .04), major bleeding, and AKI”

    Humansafter T-TEER

    Prevalence and impact of frailty on outcomes after tricuspid transcatheter edge-to-edge repair in the United States

    European Heart Journal - Valvular and Structural Heart Disease

  4. Frailty predicts acute kidney injury in humans (suspected meningoencephalitis treated with intravenous acyclovir) (79% vs. 52%, p = 0.004).

    “frailty was a strong and independent predictor of acute kidney injury, whereas chronological age and baseline renal function were not.”

    Humanssuspected meningoencephalitis treated with intravenous acyclovirwithin seven daysn = 139

    Risk factors for acute kidney injury associated with intravenous acyclovir in older adults: ACICLOAGED study

    Maturitas

  5. Frailty is linked with a higher risk of acute kidney injury in humans (undergoing transcatheter edge-to-edge repair for severe mitral regurgitation) (OR 15.91, [13.49-18.77]).

    “AKI (OR 15.91, [13.49-18.77], P<0.001)”

    Humansundergoing transcatheter edge-to-edge repair for severe mitral regurgitationn = 27,062

    Impact of frailty on outcomes of transcatheter edge-to-edge repair in severe mitral regurgitation: A nationwide readmissions database analysis

    The American journal of the medical sciences

  6. Frailty is associated with acute kidney injury in NSTEMI patients.

    “Frailty was independently associated with higher odds of complications, including acute kidney injury, respiratory failure, delirium, and bleeding.”

    Humansin NSTEMI patients

    Frailty status and outcomes of percutaneous coronary intervention in elderly patients with non-ST-elevation myocardial infarction

    World journal of cardiology

  7. Frailty is linked with a higher risk of acute kidney injury in PCI patients.

    “The incidence of stroke and acute kidney injury was also highest in frail patients.”

    Humansin PCI patients

    Frailty and Cardiovascular Outcomes in Patients Undergoing Percutaneous Coronary Intervention

    Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions

  8. Frailty is linked with a higher risk of acute kidney injury in humans (hospitalized very old patients) (aOR 2.42 [95% CI 1.93-3.03]).

    “Frailty was identified as an independent AKI risk factor {adjusted odds ratio (aOR) 2.42 [95% confidence interval (CI) 1.93-3.03]}.”

    Humanshospitalized very old patientsn = 2,132

    Acute kidney injury in very old patients-incidence, severity, risk factors and short-term outcomes

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

  9. Frailty is linked with a higher risk of acute kidney injury in humans after cardiac surgery.

    “moderate and severe frailty were associated with an increased AKI risk after cardiac surgery”

    Humansafter cardiac surgeryn = 3,569

    Association between frailty and acute kidney injury after cardiac surgery: unraveling the moderation effect of body fat through an international, retrospective, multicohort study

    International journal of surgery (London, England)

  10. Frailty is linked with a higher risk of acute kidney injury in humans (patients admitted for PFO closure) (aOR 17.6, 95% CI 9.5-32.5).

    “acute kidney injury (aOR 17.6, 95% CI 9.5-32.5)”

    Humanspatients admitted for PFO closuren = 2,063

    Impact of frailty index on cardiovascular outcomes and readmissions of patent foramen ovale closure procedure: a propensity matched national analysis

    American journal of cardiovascular disease

All 18

GLP-1 receptor agonists

downin humans13RR 0.78–0.911

13 studies
  1. GLP-1 receptor agonists are associated with acute kidney injury in humans (Use within 12 months before transcatheter aortic valve replacement) (17.9% vs 22.9%; RR 0.78).

    “Pre-procedural GLP-1 RA use was associated with decreased risks of myocardial infarction, acute kidney injury, and all-cause mortality following TAVR.”

    HumansUse within 12 months before transcatheter aortic valve replacement

    Glucagon-Like Peptide- 1 Receptor Agonists Before Transcatheter Aortic Valve Replacement: A Propensity-Matched Analysis of Mortality and Cardiorenal Protection

    AHA Scientific Sessions 2026 abstract

  2. GLP-1 receptor agonists are associated with acute kidney injury in humans (Schizophrenia, BMI ≥27 kg/m2, and antipsychotic use; compared with non-users) (HR 0.71, 95% CI 0.67–0.75).

    “lower hazards of MI (HR 0.75, 95% CI 0.68-0.82), stroke (HR 0.85, 95% CI 0.78-0.93), HF (HR 0.89, 95% CI 0.85-0.93), revascularization (HR 0.86, 95% CI 0.77-0.97), AKI (HR 0.71, 95% CI 0.67-0.75)”

    HumansSchizophrenia, BMI ≥27 kg/m2, and antipsychotic use; compared with non-users3 years

    Glucagon-Like Peptide-1 Receptor Agonists and Clinical Outcomes in Antipsychotic-Treated Patients with Schizophrenia and Obesity: A Target Trial Emulation

    AHA Scientific Sessions 2026 abstract

  3. GLP-1 receptor agonists are associated with acute kidney injury in humans (Type 2 diabetes; compared with DPP-4 inhibitors) (8.5% vs 9.4%; RR 0.911; HR 0.815).

    “Renal outcomes showed lower acute kidney injury (8.5% vs 9.4%; risk ratio 0.911; HR 0.815)”

    HumansType 2 diabetes; compared with DPP-4 inhibitors5 years

    Comparative Cardiovascular Outcomes of GLP-1 Receptor Agonists versus DPP-4 Inhibitors in Patients with Type 2 Diabetes: A Propensity Score-Matched Real-World Analysis

    AHA Scientific Sessions 2026 abstract

  4. GLP-1 receptor agonists are associated with acute kidney injury in humans (HR 0.740, 95% CI 0.650–0.842).

    “The HR for acute kidney injury during the later interval was 0.740 (95% CI, 0.650-0.842).”

    HumansMetabolic dysfunction-associated steatotic liver disease and heart failure; compared with empagliflozin or dapagliflozindays 91–1825

    GLP-1 Receptor Agonists Versus Empagliflozin or Dapagliflozin in the MASLD-Heart Failure Phenotype: An Exploratory Propensity-Matched Cohort Study

    Balkan medical journal

  5. GLP-1 receptor agonists are associated with acute kidney injury in humans (Type 2 diabetes and limb osteomyelitis; compared with non-users).

    “Compared with non-users, GLP-1RA users also had lower risks of amputation, sepsis, acute respiratory distress syndrome, and acute kidney injury.”

    HumansType 2 diabetes and limb osteomyelitis; compared with non-users

    Associations of GLP-1 Receptor Agonist Usage With Clinical Outcomes of Limb Osteomyelitis in Type 2 Diabetes

    Clinical therapeutics

  6. GLP-1 receptor agonists are associated with acute kidney injury in humans (Non-obese, non-diabetic MASLD; sustained users compared with matched non-users) (HR 0.46, 95% CI 0.26–0.81).

    “sustained GLP-1 RA use was associated with lower cardiovascular and renal event rates but not with hepatic events.”

    HumansNon-obese, non-diabetic MASLD; sustained users compared with matched non-usersFive years

    GLP-1 Receptor Agonists and Cardiorenal Outcomes in Non-Obese, Non- Diabetic MASLD: A Propensity Score-Matched Study

    Research SquarePreprint

  7. GLP-1 receptor agonists are linked with a lower risk of acute kidney injury in humans (older adults with pulmonary hypertension, compared with SGLT2I therapy) (0.792 [0.731-0.857]).

    “GLP1A use was associated with reduced risk of AKI (0.792 [0.731-0.857])”

    Humansolder adults with pulmonary hypertension, compared with SGLT2I therapy

    A19-09 Comparative Cardiopulmonary Outcomes of GLP-1 Receptor Agonists Versus SGLT2 Inhibitors in Older Adults With Pulmonary Hypertension: A Real-world Propensity-matched Analysis

    American Journal of Respiratory and Critical Care Medicine

  8. GLP-1 receptor agonists are linked with a lower risk of acute kidney injury in humans (obese patients with metformin-treated type 2 diabetes undergoing TKA) (OR 0.755; P = 0.021).

    “GLP-1RA use was associated with notable reductions in postoperative anemia (odds ratio [OR] 0.714; P = 0.001), acute kidney injury (OR 0.755; P = 0.021)”

    Humansobese patients with metformin-treated type 2 diabetes undergoing TKAn = 8,170

    Impact of GLP-1 Receptor Agonist Use on Total Knee Arthroplasty Outcomes in Metformin-Treated Diabetic Patients With and Without Comorbid Obesity: A Propensity-Matched Analysis

    The Journal of the American Academy of Orthopaedic Surgeons

  9. GLP-1 receptor agonists are associated with acute kidney injury in humans (OR 0.80; P = 0.046).

    “Acute kidney injury showed a borderline reduction (OR 0.80; P = 0.046).”

    HumansOverweight or obese adults undergoing elective laminectomy; ≥6 months of continuous preoperative therapy

    Some diabetes drugs linked to fewer spine surgery complications

    International journal of spine surgery

  10. GLP-1 receptor agonists are linked with a lower risk of acute kidney injury in humans (T2DM patients undergoing partial nephrectomy for RCC) (OR = 0.712, p < 0.05).

    “Use of GLP-1RAs was associated with lower odds of acute kidney injury (odds ratio [OR] = 0.712)”

    HumansT2DM patients undergoing partial nephrectomy for RCC

    GLP-1RA use improves outcomes post partial nephrectomy in T2DM patients with RCC: A TriNetX study

    BJUI compass

All 13

More on GLP-1 receptor agonists

Semaglutide

upin humans5downin humans4HR 0.29–0.62

9 studies
  1. Semaglutide is associated with acute kidney injury in humans (Heart failure with reduced ejection fraction and obesity; compared with no GLP-1 RA use) (HR 0.62; 95% CI 0.58–0.67).

    “Additional significant associated reductions were observed for AKI (HR 0.62; 95% CI 0.58-0.67)”

    HumansHeart failure with reduced ejection fraction and obesity; compared with no GLP-1 RA use365 days

    Semaglutide linked to fewer events in obesity with poor heart pumping

    AHA Scientific Sessions 2026 abstract

  2. Semaglutide is associated with acute kidney injury in humans (Non-Hodgkin lymphoma receiving anthracycline-based regimens) (HR 0.29, 95% CI 0.21–0.4).

    “Furthermore, a significant reduction in Acute Kidney Injury was observed (HR 0.29; 95% CI: 0.21–0.4, p<0.001)”

    HumansNon-Hodgkin lymphoma receiving anthracycline-based regimensn = 994

    Semaglutide tied to survival in non-Hodgkin lymphoma on anthracyclines

    ESC Congress 2026 abstract

  3. Semaglutide is linked with a lower risk of acute kidney injury in patients with COVID-19 compared to metformin (RR 0.73).

    “a significant risk reduction was observed for acute kidney injury (COVID-19 RR 0.73, P = .02; flu RR 0.58, P = .03) in the 30-day observation period”

    Humansin patients with COVID-19 compared to metforminkidney30-dayn = 7,092

    Semaglutide use linked to lower COVID-19 and influenza severity with better renal outcomes after pandemic or seasonal infection

    Biology methods & protocols

  4. Semaglutide is linked with a lower risk of acute kidney injury in humans (30 days after COVID-19 or influenza infection) (COVID-19 RR 0.56; flu RR 0.54).

    “and acute kidney injury (COVID-19 RR 0.56; flu RR 0.54) in the 30-day observation period”

    Humans30 days after COVID-19 or influenza infectionkidney30 days

    Semaglutide Use Linked to Lower COVID-19 and Influenza Severity with Better Cardiovascular, Pulmonary, Renal Outcomes After Pandemic or Seasonal Infection

    Preprints.orgPreprint

  5. Semaglutide is associated with acute kidney injury in humans after dose increase from 0.25 mg to 0.5 mg.

    “To our knowledge, this is a rare case of semaglutide-associated SBO and concomitant AKI requiring temporary dialysis”

    Humansafter dose increase from 0.25 mg to 0.5 mgseveral weeks of hemodialysisfemalesn = 1

    A Rare Case of Semaglutide-Associated Small Bowel Obstruction Complicated by Acute Kidney Injury Requiring Dialysis

    Cureus

  6. Semaglutide is linked with a higher risk of acute kidney injury in humans (acute kidney injury) (PRR 1.25, ROR 1.25).

    “Semaglutide showed stronger associations with diabetic ketoacidosis (DKA) (PRR 5.86, ROR 5.9) and acute kidney injury (AKI) (PRR 1.25, ROR 1.25).”

    Humansacute kidney injury

    Comparative Safety of GLP-1 Receptor Agonists Across Gastrointestinal, Renal and Pancreatic Systems

    Pharmaceuticals (Basel, Switzerland)

  7. Semaglutide is linked with a higher risk of acute kidney injury in humans (propensity-matched comparison with tirzepatide in HFpEF and obesity) (7.0% vs 6.2%; OR 1.14).

    “Acute kidney injury was also slightly higher in the Semaglutide group (7.0% vs 6.2%; OR 1.14, p=0.016)”

    Humanspropensity-matched comparison with tirzepatide in HFpEF and obesityn = 40,047

    Comparative Cardiometabolic Outcomes of Tirzepatide Versus Semaglutide in Patients with HFpEF and Obesity: A Real-World Multicenter Cohort Study

    AHA Scientific Sessions 2025 abstract

  8. Semaglutide is associated with acute kidney injury in humans (FAERS disproportionality analysis).

    “semaglutide but not tirzepatide showed a disproportionality signal for AKI”

    HumansFAERS disproportionality analysisJanuary 2022 to September 2025

    Comparative Renal Safety of Tirzepatide and Semaglutide: An FDA Adverse Event Reporting System (FAERS)-Disproportionality Study

    Journal of clinical medicine

  9. Semaglutide is associated with acute kidney injury in humans (FAERS reports, disproportionality analysis) (ROR 1.65 (1.50-1.81)).

    “semaglutide [ROR 1.65 (1.50-1.81)] and exenatide [ROR 1.14 (1.05-1.23)] showed also significant associations with the development of AKI”

    HumansFAERS reports, disproportionality analysis

    MON-527 Association of Acute kidney injury with commonly prescribed glucagon-like peptide 1 receptor Agonists: A Pharmacovigilance Analysis

    ENDO 2025 abstract

More on Semaglutide

In-hospital mortality

upin humans8HR 3.135

8 studies
  1. Acute kidney injury is associated with in-hospital mortality in humans (ICU patients) (HR 3.135, 95% CI 2.585–3.801).

    “AKI (hazard ratio 3.135, 95% CI 2.585–3.801) and age (1.039 per year) were associated with in-hospital death”

    HumansICU patientsn = 2,387

    Age and frailty linked to different intensive care outcomes

    Journal of critical care

  2. Acute kidney injury is linked with a higher risk of in-hospital mortality in humans after adjustment for CCI (OR 5.47, 95% CI 1.67–20.28).

    “operationally defined AKI was associated with in-hospital mortality after adjustment for CCI (OR 5.47, 95% CI 1.67–20.28; p = 0.005)”

    Humansafter adjustment for CCIn = 200

    Association between perioperative acute kidney injury and in-hospital mortality in patients aged 80 years and older undergoing hemiarthroplasty for femoral neck fractures: a retrospective cohort study

    BMC geriatrics

  3. Acute kidney injury is associated with in-hospital mortality in humans (hospitalized patients with COVID-19) (aHR 1.62, 95% CI 1.09 - 2.42).

    “those who developed acute kidney injury (AKI) (aHR 1.62, 95% CI 1.09 - 2.42, p=0.017) than among those who did not.”

    Humanshospitalized patients with COVID-19n = 753

    The effects of HIV and multimorbidity on the clinical outcomes of hospitalised adults with COVID‐19

    African journal of thoracic and critical care medicine

  4. Acute kidney injury is linked with a higher risk of in-hospital mortality in humans (multimorbid medical hospitalisations) (14.4% vs 4.4%, aOR 2.56 [95% CI 2.52-2.61]).

    “for the AKI group 14.4% (adjusted odds ratio [aOR] 2.56 [95% CI 2.52-2.61])”

    Humansmultimorbid medical hospitalisations

    Evaluation of health care utilisation and mortality in medical hospitalisations with multimorbidity and kidney disease, according to frailty: a nationwide cohort study

    Swiss medical weekly

  5. Acute kidney injury is linked with a higher risk of in-hospital mortality in humans (critically ill) (OR 2, 1.41-2.85).

    “in-hospital mortality (OR 2, 1.41-2.85)”

    Humanscritically illn = 1,054

    Acute kidney injury predicts mortality in very elderly critically-ill patients

    European journal of internal medicine

  6. Acute kidney injury is linked with a higher risk of in-hospital mortality in humans (adjusted for Charlson Comorbidity Index score).

    “After adjusting for the Charlson Comorbidity Index score, the AKI was associated with in-hospital mortality”

    Humansadjusted for Charlson Comorbidity Index score

    Is acute kidney injury age-dependent in older adults: an observational study in two centers from North China

    BMC geriatrics

  7. Acute kidney injury is linked with a higher risk of in-hospital mortality in humans (abdominal surgery) (23.08% vs 2.31%).

    “AKI patients had significantly longer ICU stay (3 vs 0 days; p<0.001) and higher in-hospital mortality (23.08% vs 2.31%; p<0.001)”

    Humansabdominal surgery

    Incidence, risk factors and outcomes of postoperative acute kidney injury in elderly patients undergoing abdominal surgery

    Preprint

  8. Acute kidney injury is associated with in-hospital mortality in humans (OR 3.849; 95% CI 2.874–5.155).

    “and AKI (OR 3.849; 95 % CI 2.874-5.155, p < 0.001).”

    HumansHospital admission for chronic obstructive pulmonary disease exacerbations; multivariate logistic regressionn = 7,073

    Impact of renal dysfunction on in-hospital mortality of patients with severe chronic obstructive pulmonary disease: a single-center Italian study

    International urology and nephrology

Chronic kidney disease

upin humans4upin reviews4

8 studies
  1. Acute kidney injury is linked with a higher risk of chronic kidney disease in humans following orthopaedic surgeries.

    “patients who developed AKI also had accelerated progression of chronic kidney disease compared with patients who did not develop AKI.”

    Humansfollowing orthopaedic surgeries

    The epidemiology and outcomes of acute kidney injury following orthopaedic procedures: A retrospective cohort study

    Acta anaesthesiologica Scandinavica

  2. Acute kidney injury raises the risk of chronic kidney disease in humans (neonatal AKI as a second hit).

    “Neonatal AKI is common, has a high acute mortality and is a potentially modifiable second hit towards CKD.”

    Reviewneonatal AKI as a second hitkidney

    From prematurity and low birth weight to CKD: opportunities for intervention

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

  3. Acute kidney injury raises the risk of chronic kidney disease.

    “Acute kidney injury (AKI) is a consistent precursor of incident and progressive chronic kidney disease (CKD).”

    Review

    Acute kidney injury-to-chronic kidney disease transition: Maladaptive senescence, epigenetic reprogramming, and the translational frontier

    World Advances in Renal Medicine

  4. Acute kidney injury raises the risk of chronic kidney disease (when repair is unsuccessful (failed repair)).

    “In instances where repair is unsuccessful, the kidney experiences maladaptive alterations that may progressively result in chronic kidney disease (CKD), a phenomenon referred to as failed repair.”

    Reviewwhen repair is unsuccessful (failed repair)kidney

    Mechanisms of Acute Kidney Injury-Chronic Kidney Disease Transition: Unraveling Maladaptive Repair and Therapeutic Opportunities

    Biomolecules

  5. Acute kidney injury raises the risk of chronic kidney disease in humans.

    “Acute kidney injury substantially increases the risk of chronic kidney disease progression, particularly in the elderly”

    Reviewkidney

    Tertiary lymphoid structures: chronic inflammatory microenvironments in kidney diseases

    International immunology

  6. Chronic kidney disease raises the risk of acute kidney injury.

    “CKD predisposes to acute kidney injury (AKI) which, in turn, promotes CKD progression.”

    Review

    Molecular Mechanisms of Kidney Injury and Repair

    International journal of molecular sciences

  7. Acute kidney injury raises the risk of chronic kidney disease.

    “an episode of AKI is strongly associated with an increased risk of subsequent CKD”

    Review

    Inflammaging and Complement System: A Link Between Acute Kidney Injury and Chronic Graft Damage

    Frontiers in immunology

  8. Chronic kidney disease raises the risk of acute kidney injury in humans after acute insults.

    “chronic kidney disease recognized as a major risk factor for the development of new acute kidney injury”

    Reviewafter acute insultskidney

    Acute kidney injury and chronic kidney disease: From the laboratory to the clinic

    Nephrologie & therapeutique

More on Chronic kidney disease

Frailty

upin humans6

6 studies
  1. Frailty is linked with a higher risk of acute kidney injury in humans (liver transplant recipients).

    “It was also associated with higher risks of acute kidney injury, prolonged mechanical ventilation, vasopressor requirement/hemodynamic instability, renal replacement therapy”

    Humansliver transplant recipients

    Impact of Pre-Transplant Frailty on Early Outcomes Following Liver Transplantation: A Propensity-Matched Multicenter Cohort Study

    Journal of clinical medicine

  2. Frailty is linked with a higher risk of acute kidney injury in humans (hypertensive emergency).

    “similar trends can be seen for additional outcomes such as intracerebral hemorrhage, acute kidney injury, and GI hemorrhage”

    Humanshypertensive emergency

    Impact of Frailty on In-Hospital Outcomes for Patients Admitted for Hypertensive Emergency in the United States

    AHA Scientific Sessions 2025 abstract

  3. Frailty is associated with acute kidney injury in humans (geriatric trauma).

    “Higher frailty scores correlated with increased acute kidney injury, pneumonia, urinary tract infections, and longer hospital stays.”

    Humansgeriatric trauma

    Predictors of prolonged hospitalization among geriatric trauma patients using the modified 5-Item Frailty index in a Middle Eastern trauma center: an 11-year retrospective study

    European journal of trauma and emergency surgery : official publication of the European Trauma Society

  4. Frailty is linked with a higher risk of acute kidney injury in humans (stroke) (aOR 6.96, 95% CI 6.62-7.33).

    “odds of acute renal failure were significantly higher among frail (aOR, 6.96, 95 % CI: 6.62-7.33) and pre-frail (aOR, 2.94, 95 % CI: 2.80-3.08) patients”

    Humansstroke

    Frailty among stroke patients and its effects on hospital outcomes

    Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association

  5. Frailty is linked with a higher risk of acute kidney injury in humans (hospitalized for low-energy pelvic fractures) (aOR 1.68, 95% CI: 1.56-1.82).

    “acute kidney injury (aOR = 1.68, 95 % CI: 1.56-1.82, p < 0.001)”

    Humanshospitalized for low-energy pelvic fractures

    Clinical frailty and short-term outcomes after low-energy pelvic fracture in the geriatric population: Nationwide inpatient sample 2016-2018 analysis

    Bone

  6. Frailty is associated with acute kidney injury in humans (elderly hypertensive hospitalized patients with COVID-19).

    “prevalence of acute kidney injury (AKI) was higher in the oldest old hypertensive patients and frail hypertensive patients.”

    Humanselderly hypertensive hospitalized patients with COVID-19

    Factors Affecting Mortality in Elderly Hypertensive Hospitalized Patients with COVID-19: A Retrospective Study

    Clinical interventions in aging

More on Frailty

Older age

upin humans6RR 1.09

6 studies
  1. Older age is linked with a higher risk of acute kidney injury in humans (cancer patients initiating ICIs) (RR 1.09; 95% CI 1.05 - 1.13).

    “acute kidney injury (RR 1.09; 95% CI 1.05 - 1.13)”

    Humanscancer patients initiating ICIs

    Differential Toxicity of Immune Checkpoint Inhibitors in Older Adults: A Large-Scale, Propensity Score-Matched Real-World Analysis

    Cancer investigation

  2. Older age is linked with a higher risk of acute kidney injury in humans (CAR-T recipients) (11.7% vs. 13.0% vs. 18.1%, p = 0.02).

    “Older adults had the highest rates of acute kidney injury (11.7% vs. 13.0% vs. 18.1%, p = 0.02)”

    HumansCAR-T recipients

    Impact of Age on Early CAR T-Cell Therapy Toxicity: A Propensity Score Matching Analysis

    Cancer medicine

  3. older age is linked with a higher risk of acute kidney injury in humans (STEMI treated with pPCI) (15.1% vs. 4.6%, P < 0.0001).

    “The incidence of AKI was 7%. It was 4.6% in patients <75 years and 15.1% in those ≥75 years (P < 0.0001).”

    HumansSTEMI treated with pPCIn = 5,136

    Acute kidney injury and in-hospital mortality in patients with ST-elevation myocardial infarction of different age groups

    International journal of cardiology

  4. older age is linked with a higher risk of acute kidney injury in humans (hospitalized patients aged 65 years or older compared with younger patients) (incidence 15.44% (65-79 years) and 22.22% (80 years and older)).

    “AKI incidence, in-hospital mortality, percentage of patients requiring dialysis and percentage without renal recovery were higher in elderly patients than in younger patients.”

    Humanshospitalized patients aged 65 years or older compared with younger patientsn = 42,737

    Epidemiology and outcomes of acute kidney injury in elderly chinese patients: a subgroup analysis from the EACH study

    BMC nephrology

  5. Older age is associated with acute kidney injury in humans.

    “elderly individuals experience a higher rate of acute kidney injury (AKI)”

    Reviewkidney

    Renal aging and its consequences: navigating the challenges of an aging population

    Frontiers in pharmacology

  6. Older age raises the risk of acute kidney injury in humans among users of sodium glucose cotransporter-2 inhibitors.

    “The absolute risk of acute kidney injury or acute renal failure was higher in people >65 years compared to those <65 years”

    Reviewamong users of sodium glucose cotransporter-2 inhibitors

    Acute kidney injury, renal impairment and renal failure associated with sodium glucose co-transporter-2 inhibitors in at-risk groups: A systematic review

    British journal of clinical pharmacology

C-reactive protein

upin humans4HR 1.28–1.825

4 studies
  1. C-reactive protein is associated with acute kidney injury in humans (Current alcohol consumers) (HR 1.41, 95% CI 1.34 to 1.47).

    “CRP (HR, 1.41; 95% CI, 1.34 to 1.47) and neutrophils (HR, 2.60; 95% CI, 2.25 to 3.01) associated with AKI”

    HumansCurrent alcohol consumersMedian 14.0 yearsn = 250,791

    Spirits and beer linked to acute kidney injury in UK drinkers

    Scientific reports

  2. C-reactive protein is associated with acute kidney injury in humans (CKD stages 3-5; hsCRP ≥2 mg/L) (HR 1.28 (95% CI 1.18-1.38); 3,943 events).

    “1.28 (1.18-1.38) for AKI (n=3,943)”

    HumansCKD stages 3-5; hsCRP ≥2 mg/LMedian 3.9 years65% malesn = 23,008

    High sensitivity C-reactive protein and the risk of cardio-kidney outcomes in adults with moderate to severe chronic kidney disease: a nationwide study

    Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association

  3. C-reactive protein predicts acute kidney injury in humans (obstructive sleep apnea) (11.0% versus 6.4%; HR 1.825).

    “acute kidney injury (11.0% versus 6.4%; HR 1.825), all p < 0.001.”

    Humansobstructive sleep apneafive years

    C-Reactive Protein as a Predictor of Cardiovascular Events and Mortality in Obstructive Sleep Apnea: A Propensity-Matched Analysis Using the TriNetX Research Network

    Sleep science (Sao Paulo, Brazil)

  4. C-reactive protein is linked with a higher risk of acute kidney injury in severely burned elderly patients.

    “incidences of skin infection, pneumonia, and acute kidney injury increased significantly only in the elderly group (p < 0.05).”

    Humansin severely burned elderly patients

    C-reactive protein elevation is associated with increased morbidity and mortality in elderly burned patients

    Burns : journal of the International Society for Burn Injuries

More on C-reactive protein

Dapagliflozin

downin humans1

1 study
  1. Dapagliflozin lowers the risk of acute kidney injury in humans following elective cardiac surgery (28% vs 52%).

    “Compared with placebo, dapagliflozin reduced the incidence of AKI (28% vs 52%; relative risk, 0.54 [95% CI, 0.45-0.65]; P < .001) over 7-day follow-up after surgery.”

    Human trialfollowing elective cardiac surgerykidney10 mg orally once daily4 dosesn = 784

    Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery: A Randomized Clinical Trial

    JAMA

More on Dapagliflozin

Diabetes mellitus

upin humans1

1 study
  1. Diabetes mellitus raises the risk of acute kidney injury in humans (hospitalised, multimorbid) (p < 0.05).

    “Both prevalent and incident symptomatic hypoglycaemia and incident acute kidney injury (AKI) were significantly more common in people with diabetes (p < 0.05).”

    Human trialhospitalised, multimorbidn = 1,537

    Diabetes mellitus increases risk of adverse drug reactions and death in hospitalised older people: the SENATOR trial

    European geriatric medicine

More on Diabetes mellitus

Testosterone

upin humans1

1 study
  1. Testosterone raises the risk of acute kidney injury in humans (hypogonadism and preexisting or high risk of cardiovascular disease).

    “A higher incidence of atrial fibrillation, of acute kidney injury, and of pulmonary embolism was observed in the testosterone group.”

    Human trialhypogonadism and preexisting or high risk of cardiovascular disease1.62% geldose adjusted to maintain testosterone levels between 350 and 750 ng per deciliter21.7±14.1 monthsmalesn = 5,246

    Cardiovascular Safety of Testosterone-Replacement Therapy

    The New England journal of medicine

More on Testosterone

Intensive systolic blood pressure control

upin humans1

1 study
  1. Intensive systolic blood pressure control raises the risk of acute kidney injury in humans.

    “Rates of acute kidney injury and declines of at least 30% in estimated glomerular filtration rate were increased in the intensive treatment group”

    Human trialSBP target below 120 mm Hg

    Intensive vs Standard Blood Pressure Control in Adults 80 Years or Older: A Secondary Analysis of the Systolic Blood Pressure Intervention Trial

    Journal of the American Geriatrics Society

More on Intensive systolic blood pressure control

Nicotinamide

downin humans1

1 study
  1. Nicotinamide lowers the risk of acute kidney injury.

    “AKI events were significantly lower with Nam treatment than placebo.”

    Human trial3 days (days −1, 0, and +1 relative to surgery)

    De novo NAD⁺ biosynthetic impairment in acute kidney injury in humans

    Nature medicine

More on Nicotinamide

All 166

Trial sponsors

Funding

18 grants since 2017

National Institute of Diabetes and Digestive and Kidney Diseases$13.3MFood and Drug Administration$350KGouvernement du Canada | Canadian Institutes of Health ResearchCA$830K

How this record changed

  1. Summary rewritten as its findings changed.

    As it read before

    Acute kidney injury is linked with higher mortality in hospitalized very old adults, while human studies associate frailty with higher injury risk after cardiac surgery and clonal hematopoiesis with higher injury risk. Nicotinamide mononucleotide protects mice against cisplatin-induced kidney injury, but a human trial shows no clear effect on acute kidney injury.

  2. Summary rewritten as its findings changed.

    As it read before

    Human observational studies associate frailty and PhenoAge acceleration with acute kidney injury and link injury to higher mortality in older patients. SGLT2 inhibitors are associated with lower risk in older adults with diabetes and dementia but higher risk in rheumatic heart disease. Nicotinamide mononucleotide protects mice in induced injury models but does not reduce injury in a human trial.

  3. Summary rewritten as its findings changed.

    As it read before

    Human studies link acute kidney injury to frailty, PhenoAgeAccel and clonal hematopoiesis of indeterminate potential. Trials report reduced risk with SGLT2 inhibitors in type 2 diabetes, while observational studies report lower, unchanged or higher risk across clinical populations. A mouse study reports less injury with P2RX7 antagonism in septic and aging mice, and reviews link injury to cellular senescence and dementia.

  4. Summary written from the findings.

Latest

Dec 2025: 28Jan 2026: 42Feb 2026: 45Mar 2026: 38Apr 2026: 13May 2026: 22Jun 2026: 19Jul 2026: 24Aug 2026: 34Sep 2026: 20Oct 2026: 63Nov 2026: 65413 papers in 12 months
Journal of Cachexia, Sarcopenia and Muscle

Frailty linked to death in kidney injury survivors off dialysis

Among survivors off dialysis for 90 days, moderate to severe frailty was linked to higher mortality than being fit, with an adjusted hazard ratio of 1.17.Among survivors off dialysis for 90 days, moderate to severe frailty was linked to higher mortality than being fit, with an adjusted hazard ratio of 1.17.

Cohort · 18,525 peopleBiomarkers

See all 1,067 papers on acute kidney injury